R1	Has_mood Arg1:T1 Arg2:T2	
R2	multi Arg1:T4 Arg2:T3	
R3	multi Arg1:T8 Arg2:T7	
R4	multi Arg1:T5 Arg2:T8	
R5	multi Arg1:T17 Arg2:T16	
R6	causal Arg1:T19 Arg2:T20	
R7	causal Arg1:T18 Arg2:T19	
R8	Has_qualifier Arg1:T18 Arg2:T17	
*	OR T6 T14 T13 T12 T11 T10 T18
R9	Has_temporal Arg1:T10 Arg2:T9	
R10	Has_multiplier Arg1:T6 Arg2:T5	
R11	Subsumes Arg1:T4 Arg2:T6	
R12	Has_value Arg1:T24 Arg2:T23	
R13	Has_negation Arg1:T31 Arg2:T30	
R14	Has_mood Arg1:T29 Arg2:T31	
R15	Has_mood Arg1:T32 Arg2:T31	
R16	multi Arg1:T34 Arg2:T35	
R17	multi Arg1:T33 Arg2:T34	
R18	Subsumes Arg1:T29 Arg2:T33	
R19	Subsumes Arg1:T39 Arg2:T42	
R20	multi Arg1:T46 Arg2:T47	
R21	multi Arg1:T45 Arg2:T46	
R22	Has_temporal Arg1:T43 Arg2:T45	
R23	Has_value Arg1:T43 Arg2:T44	
R24	AND Arg1:T40 Arg2:T43	
R25	Has_qualifier Arg1:T55 Arg2:T56	
R26	Has_multiplier Arg1:T55 Arg2:T54	
R27	Has_mood Arg1:T55 Arg2:T53	
*	OR T51 T52
R28	AND Arg1:T51 Arg2:T50	
R29	AND Arg1:T51 Arg2:T55	
R30	multi Arg1:T59 Arg2:T60	
R31	multi Arg1:T58 Arg2:T61	
R32	Has_temporal Arg1:T55 Arg2:T58	
R33	Has_temporal Arg1:T55 Arg2:T59	
R34	Subsumes Arg1:T4 Arg2:T15	
R35	Subsumes Arg1:T40 Arg2:T42	
R36	AND Arg1:T39 Arg2:T43	
T1	Condition 13 32	sickle cell disease
T2	Mood 0 9	Diagnosis
T3	Qualifier 34 56	Clinically significant
T4	Condition 34 64	Clinically significant disease
T5	Multiplier 103 146;76 86	per year averaged over the previous 3 years at least 1
T6	Condition 87 102	painful episode
T7	Temporal 126 146	the previous 3 years
T8	Qualifier 112 146	averaged over the previous 3 years
T9	Temporal 152 159	history
T10	Condition 163 171	priapism
T11	Condition 173 179	stroke
T12	Condition 181 201	acute chest syndrome
T13	Condition 203 221	avascular necrosis
T14	Condition 223 242	multi-organ failure
T15	Mood 250 258	need for
T16	Multiplier 259 266	chronic
T17	Qualifier 259 266	chronic
T18	Drug 267 287	narcotic medications
T19	Condition 292 296	pain
T20	Condition 302 321	sickle cell disease
T22	Non-representable 323 704	Must have failed a previous attempt at treatment with hydroxyurea defined as the inability to achieve a significant absolute increase in % fetal hemoglobin or the inability to tolerate hydroxyurea treatment due to severe side effects such as but not limited to myelosuppression, gastrointestinal symptoms, edema or hepatic enzyme elevations or have contraindications to hydroxyurea
T23	Value 706 714;722 730	18 years or older
T24	Person 718 721	age
T25	Non-representable 732 789	Hematologic laboratory values as outlined in the protocol
T26	Context_Error 732 789	Hematologic laboratory values as outlined in the protocol
T27	Context_Error 791 852	Non-hematologic laboratory values as outlined in the protocol
T28	Non-representable 791 852	Non-hematologic laboratory values as outlined in the protocol
T29	Procedure 872 884	donate blood
T30	Negation 865 868	not
T31	Mood 854 864;869 871	Must agree to
T32	Procedure 872 878;894 906	donate bodily fluid
T33	Temporal 907 934	while taking the study drug
T34	Reference_point 913 934	taking the study drug
T35	Drug 924 934	study drug
T36	Temporal 939 961	for 28 days thereafter
T39	Condition 972 995	child-bearing potential
T40	Person 963 968	Women
T42	Person 997 1001	WCBP
T43	Measurement 1024 1044	serum pregnancy test
T44	Value 1015 1023	negative
T45	Temporal 1045 1089	72 hours or less prior to starting treatment
T46	Reference_point 1071 1089	starting treatment
T47	Procedure 1080 1089	treatment
T49	Pregnancy_considerations 963 1089	Women of child-bearing potential (WCBP) must have a negative serum pregnancy test 72 hours or less prior to starting treatment
T50	Condition 1100 1123	child-bearing potential
T51	Person 1091 1096	Women
T52	Person 1128 1131	men
T53	Mood 1132 1145	must agree to
T54	Multiplier 1150 1157	2 forms
T55	Procedure 1170 1183	contraception
T56	Qualifier 1161 1169	adequate
T58	Temporal 1184 1204	prior to study entry
T59	Temporal 1209 1248	for the duration of study participation
T60	Reference_point 1229 1248	study participation
T61	Reference_point 1193 1204	study entry
